Urodynamix Applies for NIRS Medical Technology Patents

VANCOUVER, BRITISH COLUMBIA /Marketwire/ -- Urodynamix Technologies Ltd. announced that it has filed a series of applications with the U.S. Patent and Trademark Office for inventions related to medical applications of near-infrared spectroscopy (NIRS), the core technology behind the company's URO-NIRS platform.

Urodynamix has filed patent applications relating to technologies including:

  • Methods and systems for detecting Compartment syndrome
  • Methods and systems for diagnosing erectile dysfunction
  • Assessment of urinary system function by pattern matching
  • Methods for monitoring blood flow in the prostate gland
  • Digitally supported physiological sensors
  • Light intensity controls for NIRS
  • Protection against unintended light exposure

In addition, a patent application relating to the detection of urinary tract syndrome by urination onset delay in animals was submitted to the U.S. Patent and Trademark Office by the University of British Columbia (UBC), with Urodynamix employees named as co-inventors.

"These patent applications cover commercially significant opportunities for our technology and further strengthen our growing portfolio of intellectual property in medical applications of NIRS," stated Barry Allen, Urodynamix's President and CEO.

Upon the satisfaction of certain conditions, Urodynamix has agreed to issue 150,000 treasury shares to a co-inventor named on one of the patent applications in exchange for full rights to the invention.

About Urodynamix Technologies Ltd.
Urodynamix is developing a portfolio of noninvasive diagnostic products for a variety of large and growing global markets. The company is currently developing NIRS applications for urological conditions in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction, and vascular diseases. The company's disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

In June 2005, Urodynamix acquired exclusive worldwide rights to certain NIRS technology developed at UBC, including technology to aid in the diagnosis of bladder conditions, such as urinary incontinence and lower urinary tract symptoms that affect 60 million men and women in North America. Urodynamix is developing a NIRS device for noninvasive urodynamic evaluation, and in May 2007 entered into a worldwide distribution agreement with Laborie Medical Technologies, a world leader in urodynamics equipment.

Suggested Articles

The transaction has already been approved by both boards and will close in late 2021.

The overall data center system matters more than the CPU to CIOs, but investors responded poorly to Intel’s lower data centric chip sales

The world’s largest chipmaker saw a 47% decline in data center sales to enterprise and government, even as it forecast a full year 2020 record of $75B